Expion Restructures $9M Placement: Debentures Now Convert at $4.25 With $0.72 Floor

summarizeSummary

Expion amended its August $9M convertible debenture placement so the notes convert directly into common stock at $4.25 with a $0.72 floor, replacing the preferred-stock structure and keeping the $91M additional investment right as more debentures.

check_boxKey Events · Financing and Capital Events · XPON

• Placement Restructured to Common Stock

  The $9,000,000 of 8% convertible debentures due August 21, 2029 now convert directly into common stock at $4.25 instead of into Series A-1 preferred stock; the preferred designation is eliminated.

• Conversion Floor and Ratchet Added

  Conversion price cannot fall below $0.72, equal to 20% of the Nasdaq Minimum Price before the original agreement, and the price ratchets down on dilutive issuances to that floor.

• $91M Additional Investment Right Preserved

  Purchasers can still buy up to $91,000,000 of additional debentures within 18 months of the effective date; the first $10,000,000 prices at 150% of $4.25 and later tranches at the lower of $4.25 or 90% of the three lowest VWAPs.

• Shareholder Approval Still Required

  Issuance beyond 19.99% of outstanding shares needs stockholder approval; the definitive proxy for the November 4, 2026 annual meeting already seeks a 12x authorized share increase.

auto_awesomeAnalysis · XPON · Manufacturing

The August private placement no longer routes through preferred stock. The $9,000,000 of 8% debentures now convert straight into common stock at $4.25, with a hard floor of $0.72 and a ratchet that cuts the conversion price if shares are later sold cheaper. The $91,000,000 additional investment right survives but now delivers more debentures rather than preferred. For shareholders the practical change is that the entire overhang sits directly on the common stock, and the anti-dilution clause means any future discounted raise drags the conversion price down toward the floor. The company still needs shareholder approval to issue beyond 19.99% of shares outstanding, and the proxy already filed for the November 4, 2026 meeting seeks a 12x authorized share increase to make room.